Compounded vs Brand-Name GLP-1: Which Actually Saves You Money

The honest answer to "which is cheaper" is: it depends entirely on your insurance. Brand-name and compounded GLP-1s often contain the same active molecule — semaglutide or tirzepatide — but they reach you through completely different price channels. Get the channel right and you can pay a fraction of what your neighbor pays for the same result.

The two price worlds

Brand-name Wegovy and Zepbound are FDA-approved finished drugs¹² with published U.S. list prices north of $1,000 a month before any coupon or coverage. Compounded semaglutide and tirzepatide come from licensed compounding pharmacies and, across the cash-pay telehealth programs we track, run from about $58 a month at the very bottom of the market to a few hundred at the top, with a median published price near $170 (last reviewed 2026, across the programs we track). That is not a rounding difference — it's an order of magnitude. See each molecule priced separately on the current tirzepatide price ladder.

When brand-name is actually the cheaper path

If you have commercial insurance that covers Wegovy or Zepbound, or you qualify for the manufacturer savings cards, brand-name can drop to a low copay that beats any cash compounded price. In that case, paying cash for compounded would be overpaying. Check your formulary and the manufacturer savings program first — a covered brand prescription is often the single cheapest route when coverage exists. Just confirm you actually qualify, because eligibility is narrower than the ads suggest: see do GLP-1 savings cards actually lower the price?

When compounded wins on price

For the large group paying cash — no coverage, a high deductible, or a plan that excludes anti-obesity drugs — compounded is usually far cheaper. A flat $99-$149 compounded semaglutide undercuts an uncovered $1,000+ brand sticker so decisively that the comparison isn't close — see the full spread on the cheapest semaglutide ranking. This is the scenario most of our provider reviews are built for: cash-pay shoppers who want the molecule without the brand markup.

The catch: compounded isn't the same regulatory product

Cheaper comes with a trade-off worth naming. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality the way brand-name drugs are³. That doesn't make them illegitimate — it makes pharmacy verification the price of admission. Favor programs naming a LegitScript-certified or state-licensed pharmacy, and read is cheap compounded GLP-1 safe? how to vet a low price before you buy on sticker alone.

Don't compare the intro rate

When you run the compounded-vs-brand math, use the compounded program's ongoing flat price, not a first-month teaser. A $99 intro that resets to $299 changes the whole calculation. We explain the pattern in how to spot a GLP-1 teaser-rate trap — it's the easiest way to think you're saving while quietly overpaying.

Two live examples of how the compounded side gets misread. The first is a promo dressed as a rate: The Edit's advertised $109 semaglutide is $100 off one order, and the standing price underneath it is $209. The second is worse, because there is nothing to compare at all — Lighter You keeps every price behind a login and advertises a headline figure that matches none of its five programs. Use a number you can still see in month three, or leave the program out of the comparison.

The bottom line

Covered by insurance? Price the brand first — it may be your cheapest month. Paying cash? Compounded almost always wins, provided you verify the pharmacy and use the true flat rate. To put real numbers side by side, start with our Value Score reviews and compare tools, which price every program against a brand-name cash reference so the savings are auditable.

One more brand-vs-brand wrinkle worth knowing

Brand pricing isn't even consistent across a single manufacturer's own products — see Mounjaro vs Zepbound: same drug, different price for a real example where the identical molecule, from the identical company, carries two different self-pay prices depending on which brand name it's sold under. And if you've seen ads for a newer, unapproved GLP-1 promising bigger numbers than either Wegovy or Zepbound, read retatrutide: is it available yet, and is it safe to buy right now? before you go looking for it — it isn't FDA-approved, and what's being sold under that name right now carries real risk.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.